| Product NDC: | 21695-325 |
| Proprietary Name: | VYTORIN |
| Non Proprietary Name: | ezetimibe and simvastatin |
| Active Ingredient(s): | 10; 20 mg/1; mg/1 & nbsp; ezetimibe and simvastatin |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 21695-325 |
| Labeler Name: | Rebel Distributors Corp |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021687 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20040723 |
| Package NDC: | 21695-325-30 |
| Package Description: | 30 TABLET in 1 BOTTLE (21695-325-30) |
| NDC Code | 21695-325-30 |
| Proprietary Name | VYTORIN |
| Package Description | 30 TABLET in 1 BOTTLE (21695-325-30) |
| Product NDC | 21695-325 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | ezetimibe and simvastatin |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20040723 |
| Marketing Category Name | NDA |
| Labeler Name | Rebel Distributors Corp |
| Substance Name | EZETIMIBE; SIMVASTATIN |
| Strength Number | 10; 20 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Decreased Cholesterol Absorption [PE],Dietary Cholesterol Absorption Inhibitor [EPC],HMG-CoA Reductase Inhibitor [EPC],Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA] |